PTGX Q3 2024 Earnings — Protagonist Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

PTGXProtagonist Therapeutics, Inc.

$6B

Q3 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$5M

Gross Profit

$5M100.0% margin

Operating Income

-$41M-886.7% margin

Net Income

-$33M-710.4% margin

EPS (Diluted)

$-0.54

QoQ Revenue Growth

+12.2%

Cash Flow

Operating Cash Flow

-$28M

Free Cash Flow

-$29M

Stock-Based Comp.

$10M

Balance Sheet

Total Assets

$604M

Total Liabilities

$72M

Stockholders' Equity

$532M

Cash & Equivalents

$131M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$5M	$0	—
Gross Profit	$5M	$0	—
Operating Income	-$41M	-$38M	-8.2%
Net Income	-$33M	-$34M	+2.6%

Revenue Segments

Development Services

$10M100%